The single vessel process is conducive to the preparation of rivaroxaban in industry, or the use of intermediate media, the use of three-dimensional form of chemical elements or racemic mixture, with high performance and purity. Rivaroxaban is useful as an inhibitor of active coagulation form X (XA factor). Claim 1: Processing rivaroxaban, 5-chloro-n - [(5S) - 2-oxo-3 - [4 - (3-oxomorfollin-4-il) phenyl] oxazolidin-5-il] methyl] parathion-2-carboxamida in one container, preparation (1),Or a stereoisomerized isomer form or racemic mixture thereof, characterized in that (a) 5-chlorothiophosphate-2-carbonate formula (4) or a salt reacts with sulfuric acid of formula (5a) or (5b), R is a group of asphalt, cyclopentyl, halogenated tar, aralquilo, Or alternative or unsubstituted arilo； for the production of a formulated sulfuric acid compound (3),The position of R in the above definition； (b) reaction of the formula sulfonate compound (3) with the formula of 4 - [4 - [(5S) - 5 - (aminobenzene) - 2-oxo-1, 3-oxazolidin-3-il] phenyl] morphine-3-ona (2) or the form of stereochemical isomerization or racemic mixture or acid salt addition of both, Rivaroxaban (1) or stereochemical isomerization form or racemic mixture in the production formula. Claim 15: a formula sulfuric acid compound (3),Marked R is a set of asphalt, cyclomethane, halogen, aralquilo, or alternative or unsubstituted arilo.El proceso en un solo recipiente que es industrialmente ventajoso para la preparación de Rivaroxaban o una forma estereoquímicamente isomérica o una mezcla racémica de las mismas, con alto rendimiento y pureza, utilizando intermediarios. El rivaroxaban es útil como inhibidor de la forma activa de coagulación X (factor Xa). Reivindicación 1: Un proceso en un solo recipiente para preparar Rivaroxaban, 5-cloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorfolin-4-il)fenil]oxazolidin-5-il]metil]tiofeno-2-carboxamida, de fórmula (1), o una forma estereoquímicamente isomérica o una mezcla racémica de las mismas, c
